These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6098935)

  • 21. Polio antibody outfit of newborns and infants born after 20 years of mass vaccination with live poliovaccine.
    Koza J; Matyásová I; Danes L; Skovránek V; Havelková M
    J Hyg Epidemiol Microbiol Immunol; 1984; 28(1):25-32. PubMed ID: 6325534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Observations on immune persistence after vaccination with attenuated polio vaccine (author's transl)].
    Shi OS
    Zhonghua Yu Fang Yi Xue Za Zhi; 1981 May; 15(3):148-50. PubMed ID: 7307827
    [No Abstract]   [Full Text] [Related]  

  • 23. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.
    Ivanov AP; Dragunsky EM; Chumakov KM
    J Infect Dis; 2006 Feb; 193(4):598-600. PubMed ID: 16425140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
    Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of poliovirus neutralizing antibodies in young adult women.
    Mayer TR; Balfour HH
    JAMA; 1981 Sep; 246(11):1207-9. PubMed ID: 6267329
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
    Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
    Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Findings of virus-neutralizing antibodies against polioviruses in the population of Slovakia 9 and 12 years following introduction of immunization by attenuated polioviruses (author's transl)].
    Borská K; Mayerová A; Masár I; Svanigová L; Roda J; Lukácová V
    Bratisl Lek Listy; 1976 Apr; 65(4):400-6. PubMed ID: 183864
    [No Abstract]   [Full Text] [Related]  

  • 28. [Behaviour and properties of poliomyelitis coproantibodies using the "antiglobin test" and the conventional neutralisation test (author's transl)].
    Albano A; De Donato S; Scarinci V; Jakschik M
    Zentralbl Bakteriol Orig A; 1974 Feb; 226(1):1-11. PubMed ID: 4152333
    [No Abstract]   [Full Text] [Related]  

  • 29. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel.
    Swartz TA; Green MS; Handscher R; Sofer D; Cohen-Dar M; Shohat T; Habib S; Barak E; Dror Z; Somekh E; Peled-Leviathan T; Yulzari R; Libling A; Mendelson E; Shulman LM
    Vaccine; 2008 Feb; 26(8):1083-90. PubMed ID: 18241962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The use of immunomodulators to enhance postvaccinal immunity to experimental poliomyelitis].
    Bondarenko VI; Zadorozhnaia VI; Buraia TA; Gritsenko LN
    Mikrobiol Z; 1995; 57(6):41-5. PubMed ID: 8714398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroimmunity to poliomyelitis in hospital personnel.
    Tang RB; Wang HC; Lee SJ; Chang TK; Hwang B
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1984 Nov; 17(4):188-92. PubMed ID: 6099791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antibodies against poliovirus in students of a Dutch Reformed school community following the 1978 epidemic].
    Schaap GJ; Bijkerk H
    Ned Tijdschr Geneeskd; 1981 Jan; 125(5):175-81. PubMed ID: 7207667
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of the immune response of the rabbit to virulent and attenuated strains of type 1 poliovirus.
    Gaudin OG; Viac J; Thouvenot D; Sohier R
    Bull World Health Organ; 1974; 50(6):479-5. PubMed ID: 4376464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience of vaccination with inactivated poliomyelitis vaccines in Iceland.
    Gudnadóttir M
    Dev Biol Stand; 1981; 47():257-9. PubMed ID: 7227654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of an enzyme-linked immunosorbent assay based on binding inhibition for type-specific quantification of poliovirus neutralization-relevant antibodies.
    Hashido M; Horie H; Abe S; Doi Y; Hashizume S; Agboatwalla M; Isomura S; Nishio O; Hagiwara A; Inouye S
    Microbiol Immunol; 1999; 43(1):73-7. PubMed ID: 10100750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poliomyelitis vaccines: an appraisal after 25 years.
    Melnick JL
    Compr Ther; 1980 Jan; 6(1):6-14. PubMed ID: 7357844
    [No Abstract]   [Full Text] [Related]  

  • 38. [Antibody response to live trivaccine against poliomyelitis in adults].
    Koza J; Skocil V; Matyásová I; Bruj J
    Cesk Epidemiol Mikrobiol Imunol; 1984 Jul; 33(4):232-6. PubMed ID: 6091925
    [No Abstract]   [Full Text] [Related]  

  • 39. Absence of humoral immunity to poliovirus in vaccinated individuals.
    Beuen K; White R; Kobayashi R; Farrell C
    Nebr Med J; 1988 Feb; 73(2):40-4. PubMed ID: 2832773
    [No Abstract]   [Full Text] [Related]  

  • 40. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.
    Singer C; Knauert F; Bushar G; Klutch M; Lundquist R; Quinnan GV
    J Biol Stand; 1989 Apr; 17(2):137-50. PubMed ID: 2541133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.